Observation on cardiovascular safety of loratadine in treatment of persistent allergic rhinitis.
- Author:
Ying LIU
1
;
Lei CHENG
Author Information
1. Department of Otorhinolaryngology, First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. jspent@126.com
- Publication Type:Clinical Trial
- MeSH:
Administration, Oral;
Adult;
Aged;
Aged, 80 and over;
Female;
Heart Rate;
Histamine H1 Antagonists, Non-Sedating;
administration & dosage;
adverse effects;
therapeutic use;
Humans;
Loratadine;
administration & dosage;
adverse effects;
therapeutic use;
Male;
Middle Aged;
Rhinitis, Allergic, Seasonal;
drug therapy;
physiopathology;
Young Adult
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2008;22(23):1076-1078
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate cardiovascular safety of loratadine, a second generation H1-antagonist, in treatment of patients with allergic rhinitis.
METHOD:A total of 50 patients with persistent allergic rhinitis were enrolled, of which 19 cases (38.0%) had a history of cardiovascular diseases and/or presented abnormal electrocardiogram (ECG) findings without prolonged QT-interval. For all patents, 10 mg loratadine tablet was oral administrated once-daily for 30 days. ECG examinations were carried out both before and after treatment. Cardiovascular effects of loratadine were determined by the comparison of two ECGs.
RESULT:All patients had no alterations in sinus rhythm after administration of loratadine for 30 days. There were no significant differences of heart rates, P durations, PR or QRS intervals between the baseline and end-point ECGs (P > 0.05), as well as no significant prolongation of the QT or QTc corrected for heart rate using Bazett' formula (P > 0.05).
CONCLUSION:Cardiovascular safety of loratadine, a second generation H1-antagonist, is confirmed in long-term treatment of persistent allergic rhinitis at a recommended dose.
